Defining immune markers predicting protection against dengue in a long-term family study in Thailand
Official title: Defining correlates of protection from dengue illness in a long-term cohort study of multigenerational house-holds in Thailand
Funded at Upstate Medical University · NIH-11563694 · Data updated 2026-11-12
This grant looks at how antibodies develop to protect against dengue in children from a long-running family cohort in Thailand, with the goal of identifying immune signs that predict protection across multiple dengue serotypes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project start | July 10, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $149,854 |
| NIH project number | 3R01AI175941-04S2 |
| Project ID | NIH-11563694 on NIH RePORTER |
Who could benefit from this research
✓Could help
Children in Thailand who are part of the long-term multigenerational DENV cohort and are at risk for dengue exposure.
✕Less likely to help
Families outside dengue-endemic regions or individuals not enrolled in the cohort would not directly benefit from this study.
What this research studies
Researchers will use a multigenerational cohort in Kamphaeng Phet, Thailand, to study how early exposures to flaviviruses shape later dengue immune responses and clinical outcomes. The project will measure antibody titers and other immune markers in children as they experience dengue infections over time, linking immune profiles to protection or susceptibility. By comparing serotype-specific responses in a real-world, long-term setting, the study aims to define benchmarks for immune correlates of protection that could guide future vaccines and diagnostics. The effort leverages existing cohort infrastructure to observe natural infection sequences and their impact on multi-serotypic immunity.
Why it matters
Potential benefit: Identifying reliable immune correlates could inform vaccine design and improve predictions of dengue protection in children.
How similar studies have gone: Previous work in hyperendemic areas has shown that natural exposure can generate durable, multi-typic immunity, supporting the plausibility of this approach.
Where this research is happening
-
Upstate Medical University
Syracuse, United States Active
Researchers
- Principal investigator: Anderson, Kathryn B — Upstate Medical University
- Study coordinator: Anderson, Kathryn B
Related research
Other NIH-funded projects on the same topics.
-
Immune responses linked to severe dengue in children (primary infection)
This grant studies why some kids get very sick from their first dengue infection and how their immune system reacts differently from secondary infections.
-
Phase 2b trial of dengue vaccines TAK-003 and Butantan-DV to boost lasting, broad antibody protection
A trial tests whether giving a second dengue vaccine (Butantan-DV) after an initial TAK-003 shot can create stronger, longer-lasting antibodies that work against all dengue types.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
Selective GAK inhibitors to fight dengue, VEEV and other emerging viral infections
A Stanford team is testing new, selective inhibitors of GAK to block how certain viruses enter and exit cells, with the goal of a broad antiviral approach that could help people exposed to dengue, VEEV, and similar infections.
-
Understanding dengue protection in children from a long-term Thai family cohort
A long-term study in Thailand follows families to understand how early exposures to dengue shape protection and illness risk for children as they encounter the virus over time.
-
A T cell vaccine approach to prevent Dengue and Zika infections
A new vaccine approach aims to teach the immune system’s T cells to recognize and fight Dengue and Zika viruses without triggering harmful antibody responses.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.